Close Menu

NEW YORK – Biomarker test developer Biovica said today that it has inked an agreement with the SWOG Cancer Research Network to study the clinical benefit of its DiviTum immunoassay using blood samples from women with metastatic hormone receptor-positive breast cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.